Everything below concerns PPARδ agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
== Pharmacokinetics == Abacavir is given orally and is rapidly absorbed with a high bioavailability of 83%. Solution and tablet have comparable concentrations and bioavailability. Abacavir can be taken with or without food. Abacavir can cross the blood–brain barrier. Abacavir is metabolized primarily through the enzymes alcohol dehydrogenase and glucuronyl transferase to an inactive carboxylate and glucuronide metabolites. It has a half-life of approximately 1.5-2.0 hours. If a person has liver failure, abacavir's half-life is increased by 58%. Abacavir is eliminated via excretion in the urine (83%) and feces (16%). It is unclear whether abacavir can be removed by hemodialysis or peritoneal dialysis.
== Side effects == Side effects of vosilasarm in preliminary clinical studies in women with metastatic breast cancer have included vomiting (27%), dehydration (27%), constipation, decreased appetite and weight loss (27%), hypophosphatemia, decreased sex hormone-binding globulin (SHBG) levels (100%), increased prostate-specific antigen (PSA) levels (80%), and abnormal liver function tests, including elevated aspartate aminotransferase (59%), elevated alanine aminotransferase (46%), and elevated total blood bilirubin (27%). In gonadally intact male cynomolgus monkeys, vosilasarm suppressed testosterone levels by around 50% (from ~600–800 ng/dL to ~200–300 ng/dL) across three dose levels (0.01 mg/kg, 0.1 mg/kg, and 1.0 mg/kg). Changes in serum lipids, including of triglycerides, LDL cholesterol, and HDL cholesterol were also observed. Elevated liver enzymes were minimally observed in monkeys. A number of case reports of liver toxicity with non-medical use of vosilasarm have been published. A case report of acute myocarditis with non-medical use of vosilasarm also exists.
GLaDOS (Genetic Lifeform and Disk Operating System) is a rampant artificial intelligence computer system that controls Aperture Laboratories, and is the primary antagonist for the Portal series. She is voiced by Ellen McLain. She awakens the player-character Chell in the first game, tasking her through the dangerous testing course, but Chell manages to escape and appears to destroy her, though later revealed to have had her personality stored within a black box. Within the second game, Wheatley accidentally reawakens GLaDOS, and eventually convinces Chell to initiate a core transfer to replace her with himself. GLaDOS, placed into a module powered by a potato battery, is forced to work with Chell to depose Wheatley from power before the Aperture facility is destroyed. While exploring the older sections of the facility with GLaDOS's potato battery form (known informally as "PotatOS" by fans), it is revealed that her consciousness is based, at least in part, on an uploaded version of Cave Johnson's assistant, Caroline. Caroline was unwilling to be uploaded to a computer, but was forced to do so by Cave. This potentially contributed to GLaDOS's homicidal tendencies, alongside the mental adjustments and tweaking performed by the scientists working on her. In the tie-in comic Portal 2: Lab Rat, it is revealed that the personality cores, such as Wheatley, were attached to GLaDOS in an attempt to manage and control her by acting as an artificial "conscience." Discussing the morality core, scientist Doug Rattmann quips, "You can always ignore your conscience."
Following the discontinuation of Lente insulin for human use, the FDA approved a veterinary formulation derived from porcine insulin, known as Vetsulin, for daily administration in dogs and twice-daily use in cats. Insulin analogs developed for human use after Lente insulin's discontinuation have not yet been demonstrated to offer the same benefits and predictability in feline and canine patients. For this reason, along with other considerations, Lente insulin remains a widely used treatment for diabetes in both dogs and cats. Lente insulin is currently produced by Merck Animal Health under the name Vetsulin.
=== Organisation (Pre-2018) === Transportation Corps Headquarters Logistics office - Headquarters in 21 Huixin West Street, Chaoyang district, Beijing 1st Transportation Corps 1st Transportation Detachment 2nd Transportation Detachment 3rd Transportation Detachment 2nd Transportation Corps - Headquartered in Kashgar 4th Transportation Detachment 5th Transportation Detachment 6th Transportation Detachment 7th Transportation Detachment - Headquartered in Qinhuangdao 8th Transportation Detachment - Jurisdiction area Xinjiang-Tibet Highway between Rutog County and Saga County
Sources: en.wikipedia.org
=== Surgery === Wounds requiring surgical closure with skin grafts or flaps (typically anything more than a small full thickness burn) should be dealt with as early as possible. Circumferential burns of the limbs or chest may need urgent surgical release of the skin, known as an escharotomy. The aim is to release the pressure from the underlying deeper tissue and enable ventilation to the lungs and circulation to the limb . It is uncertain if it is useful for neck or digit burns. Fasciotomies may be required for electrical burns. Skin grafts can involve temporary skin substitutes, derived from animal (human donor or pig) skin or synthesized. They are used to cover the wound as a dressing, preventing infection and fluid loss, but will eventually need to be removed. Alternatively, human skin can be treated to be left on permanently without rejection. There is no evidence that the use of copper sulphate to visualise phosphorus particles for removal can help with wound healing due to phosphorus burns. Meanwhile, absorption of copper sulphate into the blood circulation can be harmful.
Globally, infants are a group that is especially vulnerable to foodborne disease. The World Health Organization has issued recommendations for the preparation, use and storage of prepared formulas. Breastfeeding remains the best preventive measure for protection from foodborne infections in infants.
=== Health and accident === On the evening of August 3, 2008, Freeman was injured in an automobile crash when his 1997 Nissan Maxima was involved in a rollover near Ruleville, Mississippi. He and his passenger, Demaris Meyer, had to be cut free from the vehicle with hydraulic tools. Freeman was conscious after the crash and joked with a photographer at the scene. He was taken via helicopter to The Regional Medical Center (The Med) hospital in Memphis. His left shoulder, arm, and elbow had been broken, and he received surgery on August 5. Doctors operated on him for four hours to repair nerve damage in his shoulder and arm. His publicist announced he was expected to make a full recovery. Although alcohol was not considered a factor in the crash, Meyer sued Freeman for negligence, claiming that he had been consuming alcohol, but the suit was eventually settled for an undisclosed amount. Freeman developed fibromyalgia following the incident, and had to switch dominant hands as his left was paralyzed. In 2010, he was diagnosed with stage 1 colon cancer and underwent a successful surgery to remove the tumor.
=== Nonsurgical === Prevention of movement between the layers allows the tentative initial bond of fibrin to be reinforced by wound healing with a thin, strong, layer of scar. Avoiding certain positions for certain surgeries may have an effect. (In abdominoplasty, sitting upright with the knees bent and hips flexed will cause pressure across the lower abdomen and a tendency to seroma formation. The patient is best to stand or at least be semirecumbent). External pressure may help in immobilization, but also is thought to reduce the tendency of the fluid to leak out of vessels by increasing the backpressure on those fluid sources. Following breast augmentation or double mastectomy, binding the chest may be recommended for several weeks to minimize the risk of seromas.
The two substrates of this enzyme are (+)-neomenthol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are (−)-menthone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (+)-neomenthol:NADP+ oxidoreductase. This enzyme is also called monoterpenoid dehydrogenase. This enzyme participates in monoterpenoid biosynthesis.
Sources: en.wikipedia.org
Glycolipid transfer proteins Lipocalins including retinol binding proteins and fatty acid-binding proteins Polyisoprenoid-binding protein, such as YceI protein domain Ganglioside GM2 activator proteins CRAL-TRIO domain (α-Tocopherol and phosphatidylinositol sec14p transfer proteins) Sterol carrier proteins Phosphatidylinositol transfer proteins and STAR domains Oxysterol-binding protein
are fitting constants. Empirical correlations allow for extremely efficient estimates of physical properties, which can be useful in thermophysical simulations. However, they require high quality experimental data to obtain a good fit and cannot reliably extrapolate beyond the conditions covered by experiments.
== External links == History of Discovery: The Tissue-Type Plasminogen Activator Story, Collen, D., Lijnen, H.R. Genentech Press Release 1982 Archived 2018-09-13 at the Wayback Machine Tissue Plasminogen Activator from the American Heart Association Widening the Window : Strategies to buy time in treating ischemic stroke - Scientific American (August 2005) Study expands window for effective stroke treatment - explained on YouTube
Beginning with his January 29, 2002 State of the Union address, Bush began publicly focusing attention on Iraq, which he labeled as part of an "axis of evil" allied with terrorists and posing "a grave and growing danger" to U.S. interests through possession of weapons of mass destruction. In the latter half of 2002, CIA reports contained assertions of Saddam Hussein's intent of reconstituting nuclear weapons programs, not properly accounting for Iraqi biological and chemical weapons, and that some Iraqi missiles had a range greater than allowed by the UN sanctions. Contentions that the Bush Administration manipulated or exaggerated the threat and evidence of Iraq's weapons of mass destruction capabilities would eventually become a major point of criticism for the president. In late 2002 and early 2003, Bush urged the United Nations to enforce Iraqi disarmament mandates, precipitating a diplomatic crisis. In November 2002, Hans Blix and Mohamed ElBaradei led UN weapons inspectors in Iraq, but were advised by the U.S. to depart the country four days prior to the U.S. invasion, despite their requests for more time to complete their tasks. The U.S. initially sought a UN Security Council resolution authorizing the use of military force but dropped the bid for UN approval due to vigorous opposition from several countries. The Bush administration's claim that the Iraq War was part of the war on terror had been questioned and contested by political analysts.
=== Legal status === In the European Economic Area, prucalopride was originally authorized for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. Subsequently, it has been authorized by the European Commission for use in all adults for the same indication.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.